BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 22553244)

  • 21. Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.
    Perez Castro S; Iñarrea Fernández A; Lamas González MJ; Sarán Diez MT; Cid Lama A; Alvarez Martín MJ; Pato Mosquera M; López-Miragaya I; Estévez N; Torres Piñón J; Oña Navarro M
    J Med Virol; 2013 Jun; 85(6):1063-8. PubMed ID: 23588733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial.
    Cotton S; Sharp L; Little J; Cruickshank M; Seth R; Smart L; Duncan I; Harrild K; Neal K; Waugh N;
    BJOG; 2010 May; 117(6):645-59. PubMed ID: 20374607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test.
    Shen Y; Gong J; He Y; Cheng G; Okunieff P; Li X
    J Virol Methods; 2013 Feb; 187(2):288-93. PubMed ID: 23201290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or.
    Han L; Husaiyin S; Zhao F; Rezhake R; Niyazi M
    Clin Lab; 2018 Sep; 64(9):1363-1371. PubMed ID: 30274003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications.
    Varnai AD; Bollmann M; Bankfalvi A; Speich N; Schmitt C; Griefingholt H; Kovács K; Klozoris C; Bollmann R
    Oncol Rep; 2008 Feb; 19(2):457-65. PubMed ID: 18202795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients.
    Benevolo M; Terrenato I; Mottolese M; Marandino F; Carosi M; Rollo F; Ronchetti L; Muti P; Mariani L; Sindico S; Vocaturo G; Vocaturo A
    Cancer Causes Control; 2011 Jun; 22(6):869-75. PubMed ID: 21424209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.
    Persson M; Brismar Wendel S; Ljungblad L; Johansson B; Weiderpass E; Andersson S
    Oncol Rep; 2012 Jul; 28(1):346-52. PubMed ID: 22484610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study.
    Broccolo F; Fusetti L; Rosini S; Caraceni D; Zappacosta R; Ciccocioppo L; Matteoli B; Halfon P; Malnati MS; Ceccherini-Nelli L
    J Med Virol; 2013 Mar; 85(3):472-82. PubMed ID: 23280876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.
    Baasland I; Romundstad PR; Eide ML; Jonassen CM
    PLoS One; 2019; 14(1):e0210997. PubMed ID: 30673759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia.
    Tropé A; Jonassen CM; Sjøborg KD; Nygård M; Dahl FA; Alfsen GC; Lie AK
    Gynecol Oncol; 2011 Nov; 123(2):257-62. PubMed ID: 21839500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study.
    Thomsen LT; Dehlendorff C; Junge J; Waldstrøm M; Schledermann D; Frederiksen K; Kjaer SK
    Int J Cancer; 2016 Oct; 139(8):1839-50. PubMed ID: 27004595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears.
    Salimović-Bešić I; Tomić-Čiča A; Smailji A; Hukić M
    J Virol Methods; 2013 Dec; 194(1-2):222-8. PubMed ID: 24036071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.
    Giorgi Rossi P; Bisanzi S; Allia E; Mongia A; Carozzi F; Gillio-Tos A; De Marco L; Ronco G; Gustinucci D; Del Mistro A; Frayle H; Iossa A; Fantacci G; Pompeo G; Cesarini E; Bulletti S; Passamonti B; Rizzi M; Penon MG; Barca A; Benevolo M
    J Clin Microbiol; 2017 Apr; 55(4):1056-1065. PubMed ID: 28100595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix.
    Cattani P; Zannoni GF; Ricci C; D'Onghia S; Trivellizzi IN; Di Franco A; Vellone VG; Durante M; Fadda G; Scambia G; Capelli G; De Vincenzo R
    J Clin Microbiol; 2009 Dec; 47(12):3895-901. PubMed ID: 19828739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.
    Duvlis S; Popovska-Jankovic K; Arsova ZS; Memeti S; Popeska Z; Plaseska-Karanfilska D
    J Med Virol; 2015 Sep; 87(9):1578-86. PubMed ID: 25880030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases.
    Li A; Li J; Austin RM; Wang T; Ashman D; Zhang H; Matsko J; Zhao C
    Cancer Cytopathol; 2021 Aug; 129(8):622-631. PubMed ID: 33764649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus DNA and E6/E7 mRNA testing as triage in liquid-based cytology samples from primary screening.
    Andersson S; Mints M; Weiderpass E; Johansson B
    Curr Pharm Des; 2013; 19(8):1508-15. PubMed ID: 23072430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women.
    Bruno MT; Ferrara M; Fava V; Rapisarda A; Coco A
    Virol J; 2018 Mar; 15(1):52. PubMed ID: 29587778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.